^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ADAM9-targeted antibody-drug conjugate

    Related drugs:
    8ms
    First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=56, Completed, ImmunoGen, Inc. | Recruiting --> Completed | N=245 --> 56 | Trial completion date: Apr 2024 --> Dec 2023
    Trial completion • Enrollment change • Trial completion date • Metastases
    |
    izeltabart tapatansine (IMGC936)
    over2years
    Preclinical Evaluation of IMGC936, a Next Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. (PubMed, Mol Cancer Ther)
    Our preclinical data provide a strong scientific rationale for the further development of IMGC936 as a therapeutic candidate for the treatment of ADAM9-positive cancers. A first-in-human study of IMGC936 in patients with advanced solid tumors has been initiated (NCT04622774).
    Preclinical • Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9)
    |
    ADAM9 expression
    |
    izeltabart tapatansine (IMGC936)
    over3years
    [VIRTUAL] IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models (AACR 2021)
    ADAM9 was highly expressed in multiple tumor types. A majority of the tumor samples had medium to high levels of ADAM9 with 62% of non-small cell lung carcinoma (NSCLC), 65% of triple negative breast cancer (TNBC), 73% of gastric cancer, and 85% of pancreatic cancer samples having H- scores of 101 to 300. The remaining tumor samples had lower levels of ADAM9 expression (H-score 1 to 100) with only 1.2% of NSCLC samples being ADAM9-negative.
    Preclinical
    |
    ADAM9 (ADAM Metallopeptidase Domain 9)
    |
    ADAM9 overexpression
    |
    izeltabart tapatansine (IMGC936)